Extracellular myocardial volume in patients with aortic stenosis

<p><strong>Background:</strong>&nbsp;Myocardial fibrosis is a key mechanism of left ventricular decompensation in aortic stenosis and can be quantified using cardiovascular magnetic resonance (CMR) measures such as extracellular volume fraction (ECV%). Outcomes following aortic...

全面介紹

書目詳細資料
Main Authors: Everett, RJ, Treibel, TA, Fukui, M, Lee, H, Rigolli, M, Singh, A, Bijsterveld, P, Tastet, L, Musa, TA, Dobson, L, Chin, C, Captur, G, Om, SY, Wiesemann, S, Ferreira, VM, Piechnik, SK, Schulz-Menger, J, Schelbert, EB, Clavel, M-A, Newby, DE, Myerson, SG, Pibarot, P, Lee, S, Cavalcante, JL, Lee, S-P, McCann, GP, Greenwood, JP, Moon, JC, Dweck, MR
格式: Journal article
語言:English
出版: Elsevier 2020
實物特徵
總結:<p><strong>Background:</strong>&nbsp;Myocardial fibrosis is a key mechanism of left ventricular decompensation in aortic stenosis and can be quantified using cardiovascular magnetic resonance (CMR) measures such as extracellular volume fraction (ECV%). Outcomes following aortic valve intervention may be linked to the presence and extent of myocardial fibrosis.</p> <p><strong>Objectives:</strong>&nbsp;This study sought to determine associations between ECV% and markers of left ventricular decompensation and post-intervention clinical outcomes.</p> <p><strong>Methods:</strong>&nbsp;Patients with severe aortic stenosis underwent CMR, including ECV% quantification using modified Look-Locker inversion recovery&ndash;based T1 mapping and late gadolinium enhancement before aortic valve intervention. A central core laboratory quantified CMR parameters.</p> <p><strong>Results:</strong>&nbsp;Four-hundred forty patients (age 70 &plusmn; 10 years, 59% male) from 10 international centers underwent CMR a median of 15 days (IQR: 4&nbsp;to&nbsp;58 days) before aortic valve intervention. ECV% did not vary by scanner manufacturer, magnetic field strength, or T1 mapping sequence (all p &gt; 0.20). ECV% correlated with markers of left ventricular decompensation including left ventricular mass, left atrial volume, New York Heart Association functional class III/IV, late gadolinium enhancement, and lower left ventricular ejection fraction (p&nbsp;&lt;&nbsp;0.05 for all), the latter 2 associations being independent of all other clinical variables (p&nbsp;=&nbsp;0.035 and p&nbsp;&lt;&nbsp;0.001). After a median of 3.8 years (IQR: 2.8 to 4.6 years) of follow-up, 52 patients had died, 14 from adjudicated cardiovascular causes. A progressive increase in all-cause mortality was seen across tertiles of ECV% (17.3, 31.6, and 52.7 deaths per 1,000 patient-years; log-rank test; p&nbsp;=&nbsp;0.009). Not only was ECV% associated with cardiovascular mortality (p&nbsp;=&nbsp;0.003), but it was also independently associated with all-cause mortality following adjustment for age, sex, ejection fraction, and late gadolinium enhancement (hazard ratio per percent increase in ECV%: 1.10; 95% confidence interval [1.02 to 1.19]; p&nbsp;=&nbsp;0.013).</p> <p><strong>Conclusions:</strong>&nbsp;In patients with severe aortic stenosis scheduled for aortic valve intervention, an increased ECV% is&nbsp;a&nbsp;measure of left ventricular decompensation and a powerful independent predictor of mortality.</p>